Using SARS-CoV-2 nucleoprotein antibodies to detect (re)infection.
Christel E Hoeve, Nienke Neppelenbroek, Eric R A Vos, Anne J Huiberts, Stijn P Andeweg, Gerco den Hartog, Robert van Binnendijk, Hester de Melker, Susan van den Hof, Mirjam Knol
Article in Epidemiology and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Christel E HoeveNational Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, The Netherlands.ORCID 0009-0005-3035-279X
Nienke NeppelenbroekNational Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, The Netherlands.
Eric R A VosNational Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, The Netherlands.
Anne J HuibertsNational Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, The Netherlands.ORCID 0000-0003-3206-9777
Stijn P AndewegNational Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, The Netherlands.
Gerco den HartogNational Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, The Netherlands.
Robert van BinnendijkNational Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, The Netherlands.
Hester de MelkerNational Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, The Netherlands.
Susan van den HofNational Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, The Netherlands.
Mirjam KnolNational Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, The Netherlands.
Funding
Ministerie van Volksgezondheid, Welzijn en Sport COVID programma 19
6 · The paper itself
Abstract
We assessed the validity of serum total anti-nucleoprotein Immunoglobulin (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Using SARS-CoV-2 nucleoprotein antibodies to detect (re)infection. · full record | OpenQuestion